VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
KYNB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
KYNBKyntra Bio, Inc.
$2.04$15M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. KYNB
  4. Financial Ratios

Kyntra Bio, Inc. (KYNB) Financial Ratios

Latest Ratios: P/E Ratio 0.2x · EV/EBITDA N/A · ROE 4099.5%. (2012–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

KYNB Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$8M$35M$53M$86M$1.5B$1.3B$3.3B$3.7B$3.9B$3.5B$1.3B
Enterprise Value$-39611795$-12374460$76M$143M$1.4B$1.2B$2.7B$3.6B$3.9B$2.9B$1.3B
P/E Ratio →0.240.19—————————
P/S Ratio1.565.511.791.8410.655.5318.9014.4818.2727.537.48
P/B Ratio1.847.93———5.687.556.947.365.947.67
P/FCF——————42.94———229.29
P/OCF——————40.84———188.90

P/E links to full P/E history page with 30-year chart

KYNB EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—-1.922.553.0610.185.2315.2814.1918.3122.957.05
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF——————34.71———216.24

KYNB Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin91.4%91.4%47.5%91.5%85.6%-90.9%95.0%99.6%-10.7%-56.4%-4.2%
Operating Margin-712.7%-712.7%-507.8%-689.5%-213.9%-122.6%-108.8%-34.8%-40.7%-97.6%-29.9%
Net Profit Margin2848.6%2848.6%-160.6%-607.3%-208.7%-123.3%-107.4%-30.0%-40.6%-100.4%-34.3%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE4099.5%4099.5%——-258.0%-86.5%-38.8%-14.5%-15.6%-33.3%-35.2%
ROA109.8%109.8%-14.9%-55.0%-42.4%-36.2%-22.5%-8.9%-9.7%-18.4%-13.1%
ROIC————-500.0%-137.3%-109.1%-13.4%-24.0%-174.8%-40.8%
ROCE-53.5%-53.5%-104.8%-119.0%-68.0%-47.6%-27.1%-11.6%-10.7%-20.0%-13.3%

KYNB Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity—————0.440.090.100.180.170.56
Debt / EBITDA———————————
Net Debt / Equity—-10.70———-0.31-1.45-0.140.01-0.99-0.44
Net Debt / EBITDA———————————
Debt / FCF——————-8.23———-13.05
Interest Coverage-6.66-6.66-17.60-38.93-203.77-324.21-77.57-25.65-6.84-11.42-4.76

Net cash position: cash ($48M) exceeds total debt ($0)

KYNB Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio3.393.391.471.521.802.104.636.847.759.694.09
Quick Ratio3.263.261.451.331.651.964.536.777.759.694.09
Cash Ratio3.043.040.381.081.541.804.215.196.989.523.89
Asset Turnover—0.050.140.110.230.300.210.300.240.140.38
Inventory Turnover0.150.154.930.100.5014.480.540.17———
Days Sales Outstanding—238.95357.11320.1642.2739.4086.70218.60109.1524.5521.24

KYNB Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield——4.2%————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield100.0%516.7%—————————
FCF Yield——————2.3%———0.4%
Buyback Yield0.8%0.2%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.8%0.2%4.2%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$4M$4M$4M$4M$4M$4M$3M$3M$3M$3M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity erosion amid losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Sub-Book Multiple Masks Operating Losses

According to reported ratio data, KYNB trades at a P/B of 1.84 and P/S of 1.56 while its trailing P/E of 0.24 rests on a one-off net profit rather than recurring earnings power, so the headline multiples are unreliable.

The trailing P/E of 0.24 is an artifact of a $148.5M net income quarter that operating results do not support, since operating margins were negative in most periods. Against peers such as PTCT at 33.75 EV/EBITDA, where earnings are positive, KYNB's multiples lack a comparable earnings anchor, which suggests investors should weight the P/S and P/B more heavily while recognizing that a stockholders' deficit makes book value an unreliable reference point.

Margins Swing on Unstable Revenue Base

Based on reported quarterly figures, KYNB's operating margin ranged from negative 46.5% to positive 74.4%, and net margin swung between negative 36.9% and positive 169.4%, indicating earnings are driven by timing rather than durable operations.

The extreme swings in gross and operating margins point to a revenue base too erratic to anchor a profitability trend, with gross margin moving from negative 31.6% to 136.3%. Compared with peers' net margins such as PTCT at 39.4% and ARWR at negative 160.6%, KYNB's figures appear largely non-representative, and investors should treat operating margin as the more informative measure of earning power while noting that non-operating items appear to dominate reported net income.

Negative Returns Erode Capital Base

As reported in the ratio table, KYNB's ROA moved from negative 13.3% to 94.2% across the period, while ROE turned positive only at 8.5% and 5.1% in recent quarters against a stockholders' deficit, leaving return metrics distorted.

A stockholders' deficit inflates or flips ROE, so the recent positive ROE figures may reflect a shrinking equity base rather than improved profitability. ROIC is largely unavailable, so the compounding question cannot be answered from this data, and the absence of consistent positive returns relative to peers such as PTCT at 60.9% ROIC suggests the capital base has not generated sustained value.

Working Capital Cycle Highly Volatile

Based on reported figures, KYNB's cash conversion cycle swung from 4,636 days to negative 133,059 days, with DSO and DPO moving erratically, indicating working capital timing dominates reported efficiency metrics.

Extreme swings in DIO and DPO, including DPO reaching 286,741 days in one period, suggest the cycle figures reflect accounting timing or balance sheet settlement rather than operational efficiency. Compared with peers, the cycle is not meaningfully comparable, and investors should treat the efficiency signal as unreliable until a stable revenue base emerges.

Current Ratio Compression Signals Pressure

As reported in the balance sheet, KYNB's current ratio compressed from 3.71 in 2025Q3 to 1.16 in 2026Q3 while cash fell to $9.9M against total liabilities of $56.0M, a position that appears thin under stress.

The quick ratio tracking the current ratio closely indicates limited reliance on inventory, but the cash buffer of $9.9M against $56.0M of liabilities leaves little room for absorbing further operating burn. The reported cash flow pattern suggests investors should monitor whether the company can sustain obligations without additional capital, though the data alone does not establish financing access.

Misapplied P/E Obscures True Risk

The most commonly misapplied metric here is trailing P/E, which at 0.24 for KYNB appears attractive but reflects a single non-recurring net income quarter rather than the negative operating earnings shown across most reported periods.

Trailing P/E is misleading because the $148.5M profit is driven by non-operating swings and working capital timing rather than core operations, so the multiple implies cheapness that operating results do not support. A more appropriate lens is EV-to-sales or cumulative operating cash flow over multiple periods, which better reflects the sustained cash burn and accumulated deficit that the headline multiple obscures.

Download Financial Ratios Data

Includes 30+ ratios · 14 years · Updated daily

Consensus & Technical Research Suite
Open KYNB Terminal

KYNB Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

KYNB — Frequently Asked Questions

Quick answers to the most common questions about buying KYNB stock.

What is Kyntra Bio, Inc.'s P/E ratio?

Kyntra Bio, Inc.'s current P/E ratio is 0.2x. The historical average is 0.2x. This places it at the 100th percentile of its historical range.

What is Kyntra Bio, Inc.'s ROE?

Kyntra Bio, Inc.'s return on equity (ROE) is 4099.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -54.1%.

Is KYNB stock overvalued?

Based on historical data, Kyntra Bio, Inc. is trading at a P/E of 0.2x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Kyntra Bio, Inc.'s profit margins?

Kyntra Bio, Inc. has 91.4% gross margin and -712.7% operating margin.